Please login to the form below

Not currently logged in
Email:
Password:

HPP

This page shows the latest HPP news and features for those working in and with pharma, biotech and healthcare.

Alexion adds to pipeline rebuild with $855m Wilson buy

Alexion adds to pipeline rebuild with $855m Wilson buy

A $1bn purchase of Enobia in 2011 gave it an enzyme therapy for the ultra-orphan disease hypophosphatasia (HPP) - Strensiq (asfotase alfa) - which made $340m in sales last year but still

Latest news

  • NICE broadens access to Alexion's rare disease drug Strensiq NICE broadens access to Alexion's rare disease drug Strensiq

    New deal offers NHS England a discount for the drug. More babies with the rare and life-threatening disease paediatric-onset hypophosphatasia (HPP) will be able to get access to ... There are up to seven cases of HPP diagnosed every year in England, and

  • AZ, BMS and Boehringer among UK Prix Galien finalists AZ, BMS and Boehringer among UK Prix Galien finalists

    asfotase alfa. Strensiq. Alexion. paediatric-onset hypophosphatasia (HPP) - bone manifestations. Real World Evidence Award 2016 finalists.

  • Alexion's rare bone disorder therapy rejected by NICE Alexion's rare bone disorder therapy rejected by NICE

    The National Institute for Health and Care Excellence (NICE) has said evidence for the drug's benefits in paediatric-onset hypophosphatasia (HPP) - a rare, inherited disorder of the bones - is not ... pain. There are around seven cases of HPP diagnosed

  • Ten new medicines recommended in Europe Ten new medicines recommended in Europe

    David Hallal, CEO of Alexion, said: “The CHMP positive opinions for Strensiq and Kanuma are significant milestones in bringing these therapies to infants, children, and adults suffering from HPP and ... Both Strensiq and Kanuma are highly innovative

  • Alexion expands in Ireland with new biofacility Alexion expands in Ireland with new biofacility

    It is however hoping to add a second from its own stable later this year - Strensiq (asfotase alfa) for hypophosphatasia (HPP) - as well as Kanuma (sebelipase alfa) for lysosomal acid lipase

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...